Neumora Therapeutics Analyst Ratings
Neumora Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | 84.33% | JP Morgan | $21 → $20 | Maintains | Overweight |
| 10/10/2023 | 93.55% | JP Morgan | → $21 | Initiates Coverage On | → Overweight |
| 10/10/2023 | 65.9% | B of A Securities | → $18 | Initiates Coverage On | → Buy |
| 10/10/2023 | — | William Blair | Initiates Coverage On | → Outperform | |
| 10/10/2023 | 102.76% | Guggenheim | → $22 | Initiates Coverage On | → Buy |
| 10/10/2023 | 121.2% | RBC Capital | → $24 | Initiates Coverage On | → Outperform |
| 10/10/2023 | 139.63% | Stifel | → $26 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/08/2023 | 84.33% | 摩根大通 | 21 美元 → 20 美元 | 维护 | 超重 |
| 2023 年 10 月 10 日 | 93.55% | 摩根大通 | → 21 美元 | 启动覆盖范围开启 | → 超重 |
| 2023 年 10 月 10 日 | 65.9% | B of A 类证券 | → 18 美元 | 启动覆盖范围开启 | → 购买 |
| 2023 年 10 月 10 日 | — | 威廉布莱尔 | 启动覆盖范围开启 | → 跑赢大盘 | |
| 2023 年 10 月 10 日 | 102.76% | 古根海姆 | → 22 美元 | 启动覆盖范围开启 | → 购买 |
| 2023 年 10 月 10 日 | 121.2% | 加拿大皇家银行资本 | → 24 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2023 年 10 月 10 日 | 139.63% | Stifel | → 26 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Neumora Therapeutics (NMRA)?
Neumora Therapeutics（NMRA）的目标价格是多少？
The latest price target for Neumora Therapeutics (NASDAQ: NMRA) was reported by JP Morgan on November 8, 2023. The analyst firm set a price target for $20.00 expecting NMRA to rise to within 12 months (a possible 84.33% upside). 7 analyst firms have reported ratings in the last year.
摩根大通于2023年11月8日公布了Neumora Therapeutics（纳斯达克股票代码：NMRA）的最新目标股价。该分析公司将目标股价定为20.00美元，预计NMRA将在12个月内升至12个月内（可能上涨84.33％）。去年有7家分析公司公布了评级。
What is the most recent analyst rating for Neumora Therapeutics (NMRA)?
Neumora Therapeutics（NMRA）的最新分析师评级是多少？
The latest analyst rating for Neumora Therapeutics (NASDAQ: NMRA) was provided by JP Morgan, and Neumora Therapeutics maintained their overweight rating.
摩根大通对Neumora Therapeutics（纳斯达克股票代码：NMRA）的最新分析师评级由摩根大通提供，Neumora Therapeutics维持增持评级。
When is the next analyst rating going to be posted or updated for Neumora Therapeutics (NMRA)?
Neumora Therapeutics（NMRA）的下一份分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neumora Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neumora Therapeutics was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Neumora Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Neumora Therapeutics的最新评级是在2023年11月8日公布的，因此您应该预计下一个评级将在2024年11月8日左右公布。
Is the Analyst Rating Neumora Therapeutics (NMRA) correct?
分析师对Neumora Therapeutics（NMRA）的评级是否正确？
While ratings are subjective and will change, the latest Neumora Therapeutics (NMRA) rating was a maintained with a price target of $21.00 to $20.00. The current price Neumora Therapeutics (NMRA) is trading at is $10.85, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Neumora Therapeutics（NMRA）评级维持不变，目标股价为21.00美元至20.00美元。Neumora Therapeutics（NMRA）目前的交易价格为10.85美元，超出了分析师的预期区间。